Gilberta Giacchetti

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4283190/gilberta-giacchetti-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62 papers	5,295 citations	36 h-index	65 g-index
65 ext. papers	6,057 ext. citations	5.3 avg, IF	4.52 L-index

#	Paper	IF	Citations
62	Remote management of osteoporosis in the first wave of the COVID-19 pandemic.. *Archives of Osteoporosis*, **2022**, 17, 37	2.9	0
61	Bone Metabolism in SARS-CoV-2 Disease: Possible Osteoimmunology and Gender Implications. *Clinical Reviews in Bone and Mineral Metabolism*, **2020**, 18, 1-7	2.5	17
60	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. *International Journal of Cardiology: Hypertension*, **2020**, 5, 100029	1.6	24
59	Primary Aldosteronism and Obstructive Sleep Apnea: A Cross-Sectional Multi-Ethnic Study. *Hypertension*, **2019**, 74, 1532-1540	8.5	19
58	Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. *Hypertension*, **2018**, 71, 585-591	8.5	95
57	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. *Hypertension*, **2018**, 72, 641-649	8.5	54
56	Quantitative Value of Aldosterone-Renin Ratio for Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) Study. *Journal of the American Heart Association*, **2017**, 6,	6	41
55	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 689-699	18.1	355
54	Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism. *Endocrine*, **2016**, 54, 826-829	4	2
53	Hypovitaminosis D and organ damage in patients with arterial hypertension: a multicenter double blind randomised controlled trial of cholecalciferol supplementation (HYPODD) : study design, clinical procedures and treatment protocol. *High Blood Pressure and Cardiovascular Prevention*, **2015**, 22, 135-42	2.9	3
52	Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. *Hypertension*, **2014**, 63, 188-95	8.5	126
51	Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. *Hypertension*, **2014**, 64, 354-61	8.5	211
50	Aldosterone suppression on contralateral adrenal during adrenal vein sampling does not predict blood pressure response after adrenalectomy. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 4158-66	5.6	50
49	Cortical adrenal mitochondrial morphology changes in functional state: new insights. *Cell and Tissue Research*, **2013**, 351, 409-17	4.2	3
48	Visceral adipose tissue: emerging role of gluco- and mineralocorticoid hormones in the setting of cardiometabolic alterations. *Annals of the New York Academy of Sciences*, **2012**, 1264, 87-102	6.5	30
47	Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism. *Hypertension*, **2012**, 59, 840-6	8.5	74
46	Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. *Current Vascular Pharmacology*, **2012**, 10, 238-46	3.3	17

45	Progesterone increase counteracts aldosterone action in a pregnant woman with primary aldosteronism. *Clinical Endocrinology*, **2011**, 74, 278-9	3.4	20
44	Complicanze cardiometaboliche e renali nell'iperaldosteronismo primario. *L Endocrinologo*, **2011**, 12, 111-116	0	
43	Blood pressure, thyroid-stimulating hormone, and thyroid disease prevalence in primary aldosteronism and essential hypertension. *American Journal of Hypertension*, **2011**, 24, 1274-9	2.3	9
42	Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. *Hypertension*, **2010**, 55, 83-9	8.5	54
41	The functional c.-2G>C variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels. *Hypertension*, **2010**, 56, 995-1002	8.5	40
40	Gitelman syndrome, calcium pyrophosphate dihydrate deposition disease and crowned dens syndrome. A new association?. *Rheumatology*, **2010**, 49, 610-3	3.9	8
39	Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 4037-42	5.6	39
38	Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 1541-7	5.6	227
37	Small tumor size as favorable prognostic factor after adrenalectomy in Conn's adenoma. *European Journal of Endocrinology*, **2009**, 160, 639-46	6.5	19
36	Ipo- e iperpotassiemie nella pratica clinica: percorsi diagnostici e terapeutici. *L Endocrinologo*, **2009**, 10, 2-15	0	
35	Management of primary aldosteronism: its complications and their outcomes after treatment. *Current Vascular Pharmacology*, **2009**, 7, 244-49	3.3	12
34	AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. *FASEB Journal*, **2008**, 22, 1672-83	0.9	121
33	Adipose cell-adrenal interactions: current knowledge and future perspectives. *Trends in Endocrinology and Metabolism*, **2008**, 19, 100-3	8.8	20
32	Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis. *Trends in Endocrinology and Metabolism*, **2008**, 19, 104-8	8.8	31
31	Primary aldosteronism: cardiovascular, renal and metabolic implications. *Trends in Endocrinology and Metabolism*, **2008**, 19, 88-90	8.8	170
30	Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertension. *Canadian Journal of Physiology and Pharmacology*, **2008**, 86, 505-10	2.4	37
29	Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 2566-71	5.6	141
28	Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 4969-73	5.6	66

27	Diagnosis and management of primary aldosteronism. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2008**, 15, 332-8	4	14
26	Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. *Hypertension*, **2007**, 50, 424-31	8.5	120
25	Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. *Journal of Hypertension*, **2007**, 25, 1433-42	1.9	67
24	Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. *Journal of Hypertension*, **2007**, 25, 177-86	1.9	132
23	Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. *European Journal of Endocrinology*, **2006**, 155, 435-41	6.5	56
22	A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 5083-9	5.6	169
21	A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *Journal of the American College of Cardiology*, **2006**, 48, 2293-300	15.1	990
20	Renal damage in primary aldosteronism: results of the PAPY Study. *Hypertension*, **2006**, 48, 232-8	8.5	351
19	Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism. *Journal of Hypertension*, **2006**, 24, 1899-1900	1.9	1
18	Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. *Journal of Hypertension*, **2006**, 24, 737-45	1.9	104
17	The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. *Trends in Endocrinology and Metabolism*, **2005**, 16, 120-6	8.8	197
16	Diagnosis of primary aldosteronism: from screening to subtype differentiation. *Trends in Endocrinology and Metabolism*, **2005**, 16, 114-9	8.8	112
15	Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. *American Journal of Hypertension*, **2005**, 18, 1091-8	2.3	44
14	Reduced nitric oxide levels in acromegaly: cardiovascular implications. *Blood Pressure*, **2005**, 14, 227-32	1.7	26
13	Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. *Hypertension*, **2003**, 42, 123-9	8.5	49
12	Insulin receptors and renal sodium handling in hypertensive fructose-fed rats. *Kidney International*, **2003**, 64, 2163-71	9.9	72
11	Cellular mechanisms of insulin resistance in rats with fructose-induced hypertension. *American Journal of Hypertension*, **2003**, 16, 973-8	2.3	110
10	Severe hypomagnesaemia-induced hypocalcaemia in a patient with Gitelman's syndrome. *Clinical Endocrinology*, **2002**, 56, 413-8	3.4	12

9	Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. *American Journal of Hypertension*, **2002**, 15, 381-8	2.3	142
8	Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. *American Journal of Hypertension*, **2001**, 14, 382-6	2.3	58
7	The tissue renin-angiotensin system in rats with fructose-induced hypertension: overexpression of type 1 angiotensin II receptor in adipose tissue. *Journal of Hypertension*, **2000**, 18, 695-702	1.9	58
6	CA-Repeat polymorphism in intron 1 of HSD11B2 : effects on gene expression and salt sensitivity. *Hypertension*, **2000**, 36, 187-94	8.5	125
5	Genotype-phenotype correlations of mutations and polymorphisms in HSD11B2, the gene encoding the kidney isozyme of 11beta-hydroxysteroid dehydrogenase. *Endocrine Research*, **2000**, 26, 771-80	1.9	26
4	Polymorphisms of angiotensin-converting enzyme and angiotensinogen genes in type 2 diabetic sibships in relation to albumin excretion rate. *American Journal of Kidney Diseases*, **1999**, 34, 1002-9	7.4	20
3	Ontogenic expression of renal and hepatic angiotensin II receptor genes in the rat. *Nephron*, **1997**, 76, 103-10		9
2	Abnormalities of insulin receptors in spontaneously hypertensive rats. *Hypertension*, **1996**, 27, 955-61	8.5	35
1	Tissue-specific regulation of type 1 angiotensin II receptor mRNA levels in the rat. *Hypertension*, **1996**, 28, 403-8	8.5	61